Penny Nymark
Research Specialist
E-mail: penny.nymark@ki.se
Visiting address: Nobels väg 13, 17177 Stockholm
Postal address: C6 Institutet för miljömedicin, C6 Ledningskansliet, 171 77 Stockholm
About me
- I am a researcher at the Institute of Environmental Medicine at Karolinska
Institutet with a background in genetics, cancer and toxicology. In recent
years, my main focus has turned towards development of Adverse Outcome
Pathways (AOPs) and New Approach Methodologies (NAMs), as well as their
application in risk assessment and in safe and sustainable development of new
technologies. Coupled to this focus, I also have a broad interest in making
data Findable, Accessible, Interoperable and Reusable (FAIR). In addition to
research, I function as coordinator within the Swedish platform for
Nanosafety, SweNanoSafe [1], where I focus on communication, education and
sustainability (e.g. Safe and Sustainable by Design, SSbD) aspects within
nanosafety.
*Ongoing projects and involvements:*
Toward risk assessment without animals: Development of Adverse Outcome
Pathways for lung cancer [2]
PARC [3]- European Partnership for the Assessment of Risks from Chemicals
HARMLESS [4] - Advanced high aspect ratio multicomponent materials: towards
comprehensive intelligent testing and safe by design strategies
*Selected previous projects and involvements:*
Gov4Nano [5] - Implementation of Risk Governance: meeting the needs of
nanotechnology
eNanoMapper [6] - A Database and Ontology Framework for Nanomaterials Design
and Safety Assessment
NANoREG [7] - A common European approach to the regulatory testing of
nanomaterials
NANOSOLUTIONS [8] - Biological Foundation for the Safety Classification of
Engineered Nanomaterials (ENM): Systems Biology Approaches to Understand
Interactions of ENM with Living Organisms and the Environment
NanoReg2 [9] - Development and implementation of Grouping and Safe-by-Design
approaches within regulatory frameworks
caLIBRAte [10] - Performance testing, calibration and implementation of a
next generation system-of-systems Risk Governance Framework for nanomaterials
PATROLS [11] – Physiologically Anchored Tools for Realistic nanOmateriaL
hazard aSsessment
NanoSolveIT [12] – Innovative Nanoinformatics models and tools: towards a
Solid, verified and Integrated Approach to Predictive (eco)Toxicology
miRNAno [13] - Toxicogenomic studies on engineered carbon nanomaterials
Application of the Adverse Outcome Pathway concept and bioinformatics for
mechanistic understanding of COVID-19 [14]
[1] https://swenanosafe.ki.se/
[2] https://ki.se/en/imm/toward-risk-assessment-without-animals-development-of-adverse-outcome-pathways-for-lung-cancer
[3] https://news.ki.se/unique-eu-project-to-develop-next-generation-chemical-risk-assessment
[4] https://www.harmless-project.eu/
[5] https://www.gov4nano.eu/
[6] http://www.enanomapper.net/
[7] https://cordis.europa.eu/project/id/310584
[8] https://cordis.europa.eu/project/id/309329
[9] https://cordis.europa.eu/project/id/646221
[10] https://cordis.europa.eu/project/id/686239
[11] https://www.patrols-h2020.eu/
[12] https://nanosolveit.eu/
[13] https://cordis.europa.eu/project/id/299525
[14] https://ki.se/en/imm/application-of-the-adverse-outcome-pathway-concept-and-bioinformatics-for-mechanistic
Research
- *Selected publications:*
Wittwehr C, Clerbaux LA, Edwards S, Angrish M, Mortensen H, Carusi A,
Gromelski M, Lekka E, Virvilis V, Martens M, Bonino da Silva Santos
LO, *Nymark P. *Why adverse outcome pathways need to be FAIR. [1] ALTEX.
2023 Aug 1. doi: 10.14573/altex.2307131. Online ahead of print.
Dumit, V. I., Ammar, A., Bakker, M. I., Bañares, M. A., Bossa, C., Costa,
A., Cowie, H., Drobne, D., Exner, T. E., Farcal, L., Friedrichs, S., Furxhi,
I., Grafström, R., Haase, A., Himly, M., Jeliazkova, N., Lynch, I., Maier,
D., Noorlander, C. W., ... *Nymark, P*. (2023). From principles to reality.
FAIR implementation in the nanosafety community. [2] /Nano Today/, /51/,
[101923]. doi: 10.1016/j.nantod.2023.101923
Grafström R, Haase A, Kohonen P, Jeliazkova N, *Nymark P. *Reply to:
Prospects and challenges for FAIR toxicogenomics data. [3] Nat Nanotechnol.
2021 Dec 23. doi: 10.1038/s41565-021-01050-8. Online ahead of print.
Lynch I, *Nymark P*, Doganis P, Gulumian M, Yoon TH, Martinez DST, Afantitis
A. Methods, models, mechanisms and metadata: Introducing the Nanotoxicology
collection at F1000Research. [4] F1000Res. 2021 Nov 24 - 10:1196. doi:
10.12688/f1000research.75113.1. eCollection 2021.
Bossa C, Andreoli C, Bakker M, Barone F, De Angelis I, Jeliazkova N, *Nymark
P*, Battistelli CL. FAIRification of nanosafety data to improve
applicability of (Q)SAR approaches: A case study on /in vitro/ Comet assay
genotoxicity data. [5] Comput Toxicol. 2021 Nov - 20:100190. doi:
10.1016/j.comtox.2021.100190.
Jeliazkova N, Apostolova MD, Andreoli C, Barone F, Barrick A, Battistelli C,
Bossa C, Botea-Petcu A, Châtel A, De Angelis I, Dusinska M, El Yamani N,
Gheorghe D, Giusti A, Gómez-Fernández P, Grafström R, Gromelski M,
Jacobsen NR, Jeliazkov V, Jensen KA, Kochev N, Kohonen P, Manier N, Mariussen
E, Mech A, Navas JM, Paskaleva V, Precupas A, Puzyn T, Rasmussen K, Ritchie
P, Llopis IR, Rundén-Pran E, Sandu R, Shandilya N, Tanasescu S, Haase A,
*Nymark P.* Towards FAIR nanosafety data. [6]Nat Nanotechnol. 2021 May 20.
doi: 10.1038/s41565-021-00911-6.
*Nymark P*, Karlsson HL, Halappanavar S, Vogel U. Adverse Outcome Pathway
development for assessment of lung carcinogenicity by nanoparticles [7].
Frontiers in Toxicology, 29 April 2021. doi: 10.3389/ftox.2021.653386
*Nymark P, * Sachana M, Batista-Leite S, Sund J, Krebs C.E., Sullivan K,
Edwards S, Viviani L, Willett K, Landesmann B, Wittwehr C. Systematic
Organization of COVID-19 Data Supported by the Adverse Outcome Pathway
Framework [8]. Frontiers in Public Health, 19 May 2021, doi:
10.3389/fpubh.2021.638605
Halappanavar S, van den Brule S, * Nymark P*, Gaté L, Seidel C, Valentino S,
Zhernovkov V, Høgh Danielsen P, De Vizcaya A, Wolff H, Stöger T, Boyadziev
A, Poulsen SS, Sørli JB, Vogel U. Adverse outcome pathways as a tool for the
design of testing strategies to support the safety assessment of emerging
advanced materials at the nanoscale. [9] Part Fibre Toxicol. 2020 May
25 - 17(1):16. doi: 10.1186/s12989-020-00344-4.
*Nymark P*, Bakker M, Dekkers S, Franken R, Fransman W, García-Bilbao A,
Greco D, Gulumian M, Hadrup N, Halappanavar S, Hongisto V, Hougaard KS,
Jensen KA, Kohonen P, Koivisto AJ, Dal Maso M, Oosterwijk T, Poikkimäki M,
Rodriguez-Llopis I, Stierum R, Sørli JB, Grafström R. Toward Rigorous
Materials Production: New Approach Methodologies Have Extensive Potential to
Improve Current Safety Assessment Practices. [10]Small. 2020
Feb - 16(6):e1904749. doi: 10.1002/smll.201904749. Epub 2020 Jan 8.
Soeteman-Hernandez LG, Apostolova MD, Bekker C, Dekkers S, Grafström RC,
Groenewold M, Handzhiyski Y, Herbeck-Engel P, Hoehener K, Karagkiozaki V,
Kelly S, Kraegeloh A, Logothetidis S, Micheletti C, *Nymark P*, Oomen A,
Oosterwijk T, Rodríguez-LLopis I, Sabella S, Sanchez Jiménez A, Sips A,
Suarez-Merino B, Tavernaro I, van Engelen J, Wijnhoven SWP, Noorlander CW.
Safe innovation approach: Towards an agile system for dealing with
innovations. [11] Materials Today Communications, Volume 20, 2019, 100548,
ISSN 2352-4928, doi: 10.1016/j.mtcomm.2019
Giusti A, Atluri R, Tsekovska R, Gajewicz A, Apostolova MD, Battistelli CL,
Bleeker EAJ, Bossa C, Bouillard j, Dusinska M, Gómez-Fernández P,
Grafström R, Gromelski M, Handzhiyski Y, Jacobsen NR, Jantunen P, Jensen KA,
Mech A, Navas JM, *Nymark P*, Oomen AG, Puzyn T, Rasmussen K, Riebeling C,
Rodriguez-Llopis I, Sabella S, Riego Sintes J, Suarez-Merino B, Tanasescu S,
Wallin H, Haase A. Nanomaterial grouping: Existing approaches and future
recommendations [12]. NanoImpact, Volume 16, 2019, 100182, ISSN 2452-0748,
doi: 10.1016/j.impact.2019.100182
*Nymark P*, Kohonen P, Hongisto V, Grafström RC. Toxic and Genomic
Influences of Inhaled Nanomaterials as a Basis for Predicting Adverse
Outcome. [13]Ann Am Thorac Soc. 2018 Apr - 15(Suppl 2):S91-S97. doi:
10.1513/AnnalsATS.201706-478MG.
*Nymark P*, Rieswijk L, Ehrhart F, Jeliazkova N, Tsiliki G, Sarimveis H,
Evelo CT, Hongisto V, Kohonen P, Willighagen E, Grafström RC. A Data Fusion
Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions.
[14]Toxicol Sci. 2018 Mar 1 - 162(1):264-275. doi: 10.1093/toxsci/kfx252.
*Nymark P*, Wijshoff P, Cavill R, van Herwijnen M, Coonen ML, Claessen S,
Catalán J, Norppa H, Kleinjans JC, Briedé JJ. Extensive temporal
transcriptome and microRNA analyses identify molecular mechanisms underlying
mitochondrial dysfunction induced by multi-walled carbon nanotubes in human
lung cells. [15] Nanotoxicology, 2015. 9(5): p. 624-635. doi:
10.3109/17435390.2015.1017022
*Nymark P*, Guled M, Borze I, Faisal A, Lahti L, Salmenkivi K, Kettunen E,
Anttila S, Knuutila S. Integrative Analysis of microRNA, mRNA and aCGH Data
Reveals Asbestos-Related Changes in Non-Small Cell Lung Cancer. [16] Genes,
Chromosom. Cancer, 2011. 50(8):585-97. doi: 10.1002/gcc.20880
*Nymark P*, Wikman H, Hienonen-Kempas T, Anttila S. Molecular and genetic
changes in asbestos-related lung cancer [17]. Cancer Lett. 2008. 265(1):1-15.
Doi: 10.1016/j.canlet.2008.02.043
[1] https://pubmed.ncbi.nlm.nih.gov/37528748/
[2] https://doi.org/10.1016/j.nantod.2023.101923
[3] https://doi.org/10.1038/s41565-021-01050-8
[4] https://doi.org/10.12688/f1000research.75113.1
[5] https://doi.org/10.1016/j.comtox.2021.100190
[6] https://doi.org/10.1038/s41565-021-00911-6
[7] https://doi.org/10.3389/ftox.2021.653386
[8] https://doi.org/10.3389/fpubh.2021.638605
[9] https://pubmed.ncbi.nlm.nih.gov/32450889/
[10] https://pubmed.ncbi.nlm.nih.gov/31913582/
[11] https://doi.org/10.1016/j.mtcomm.2019
[12] https://doi.org/10.1016/j.impact.2019.100182
[13] https://pubmed.ncbi.nlm.nih.gov/29676641/
[14] https://pubmed.ncbi.nlm.nih.gov/29149350/
[15] http://doi.org/10.3109/17435390.2015.1017022
[16] http://doi.org/10.1002/gcc.20880
[17] http://doi.org/10.1016/j.canlet.2008.02.043
Teaching
- *Teaching:*
I am course leader for the PhD course /Human Cell Culture. Methods and
Applications/. (code 3127). I also lead course modules in the Master Program
in Toxicology, including on bioinformatics and omics, as well as a workshop
on toxicological high-throughput screening assays and data (ToxCast
workshop). Furthermore, I provide a number of lectures both at KI and other
universities and external courses in the areas of human cell culture methods,
alternative (3R) methods, toxicogenomics and systems toxicology,
bioinformatics, high-throughput screening approaches, data management (FAIR
principles), Adverse Outcome Pathways (AOPs) and Safe and Sustainable by
Design (SSbD).
Articles
- Article: COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2024;25:105-126
- Article: ADVANCED SCIENCE. 2024;11(9):e2306268
- Article: ALTEX. 2024;41(1):50-56
- Article: ALTEX. 2024;41(2):233-247
- Journal article: TOXICOLOGY LETTERS. 2023;384:s105-S108
- Article: NANO TODAY. 2023;51:101923
- Journal article: ANNALS OF WORK EXPOSURES AND HEALTH. 2023;67(Supplement_1):i65-i66
- Article: JOURNAL OF CHEMINFORMATICS. 2023;15(1):34
- Article: FRONTIERS IN TOXICOLOGY. 2023;5:1319985
- Article: FRONTIERS IN TOXICOLOGY. 2023;5:1183824
- Article: JOURNAL OF CHEMINFORMATICS. 2022;14(1):57
- Article: NANOIMPACT. 2022;27:100402
- Article: FRONTIERS IN ONCOLOGY. 2022;12:849640
- Article: ALTEX. 2022;39(2):322-335
- Journal article: F1000RESEARCH. 2021;10:elixir-1129
- Article: COMPUTATIONAL TOXICOLOGY. 2021;20:100190
- Article: NATURE NANOTECHNOLOGY. 2021;16(6):644-654
- Article: NANOMATERIALS. 2021;11(3):639
- Article: FRONTIERS IN TOXICOLOGY. 2021;3:653386
- Article: FRONTIERS IN PUBLIC HEALTH. 2021;9:638605
- Article: F1000RESEARCH. 2021;10:ELIXIR-1129
- Article: MATERIALS TODAY COMMUNICATIONS. 2019;20:100548
- Article: JOURNAL OF CHEMICAL INFORMATION AND MODELING. 2018;58(3):543-549
- Article: TOXICOLOGICAL SCIENCES. 2018;162(1):264-275
- Article: FRONTIERS IN GENETICS. 2018;9:661
- Article: SMALL METHODS. 2017;1(11)
- Article: NANOTOXICOLOGY. 2016;10(6):794-806
- Article: ATLA ALTERNATIVES TO LABORATORY ANIMALS. 2015;43(5):325-332
- Article: PARTICLE AND FIBRE TOXICOLOGY. 2014;11:4
- Article: TOXICOLOGY. 2013;313(1):38-48
- Journal article: CANCER RESEARCH. 2013;73(8_Supplement):627
- Article: MOLECULAR ONCOLOGY. 2013;7(1):29-40
- Article: GENES CHROMOSOMES AND CANCER. 2011;50(8):585-597
- Article: BRITISH JOURNAL OF CANCER. 2009;100(8):1336-1342
- Article: CLINICAL CANCER RESEARCH. 2009;15(2):468-475
- Article: CARCINOGENESIS. 2008;29(5):913-917
- Journal article: JOURNAL OF THORACIC ONCOLOGY. 2007;2(8):s487
- Journal article: JOURNAL OF THORACIC ONCOLOGY. 2007;2(8):s491
- Article: ONCOGENE. 2007;26(32):4730-4737
- Article: BMC GENOMICS. 2007;8:62
- Article: CANCER RESEARCH. 2006;66(11):5737-5743
- Article: GENES CHROMOSOMES AND CANCER. 2005;42(2):193-199
- Show more
All other publications
- Review: NATURE PROTOCOLS. 2024;19(11):2642-2684
- Review: NANOTOXICOLOGY. 2024;18(4):373-400
- Conference publication: TOXICOLOGY LETTERS. 2023;384:s310-S317
- Conference publication: TOXICOLOGY LETTERS. 2023;384:s256-S262
- Conference publication: TOXICOLOGY LETTERS. 2023;384:S105
- Conference publication: TOXICOLOGY LETTERS. 2023;384:S310
- Editorial comment: NATURE NANOTECHNOLOGY. 2022;17(1):19-20
- Conference publication: TOXICOLOGY LETTERS. 2021;350:S60
- Conference publication: TOXICOLOGY LETTERS. 2021;350:S9-S10
- Conference publication: TOXICOLOGY LETTERS. 2021;350:S38
- Preprint: CHEMRXIV. 2021
- Preprint: CHEMRXIV. 2021
- Review: SMALL. 2021;17(15):e2006055
- Review: SMALL. 2021;17(15):e2007628
- Preprint: PREPRINTS.ORG. 2021
- Editorial comment: F1000RESEARCH. 2021;10:1196
- Corrigendum: NANOIMPACT. 2021;21
- Editorial comment: ALTEX. 2021;38(2):351-357
- Review: PARTICLE AND FIBRE TOXICOLOGY. 2020;17(1):16
- Review: NANOMATERIALS. 2020;10(5):E903-903
- Review: NANOMATERIALS. 2020;10(4):E750-750
- Review: NANOMATERIALS. 2020;10(4):E708-708
- Review: SMALL. 2020;16(6):e1904749
- Book chapter: OCCUPATIONAL CANCERS. 2020;p. 227-238
- Review: COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2020;18:583-602
- Review: NANOIMPACT. 2019;16:100182
- Review: NANOTOXICOLOGY. 2019;13(1):119-141
- Conference publication: TOXICOLOGY LETTERS. 2019;314:S202-S203
- Conference publication: TOXICOLOGY LETTERS. 2019;314:S69
- Conference publication: TOXICOLOGY LETTERS. 2019;314:S62-S63
- Conference publication: TOXICOLOGY LETTERS. 2019;314:S25
- Meeting abstract: TOXICOLOGY LETTERS. 2018;295:S227-S228
- Published conference paper: ANNALS OF THE AMERICAN THORACIC SOCIETY. 2018;15(Suppl 2):S91-S97
- Book chapter: NANOTOXICOLOGY: ISSUES IN TOXICOLOGY. 2017;p. 276-303
- Meeting abstract: TOXICOLOGY LETTERS. 2016;258:S118-S119
- Book chapter: CANCER CYTOGENETICS. 2015;p. 361-372
- Book chapter: OCCUPATIONAL CANCERS. 2014;p. 243-251
- Book chapter: OCCUPATIONAL CANCERS. 2014;p. 211-230
- Meeting abstract: TOXICOLOGY LETTERS. 2012;211:S205
- Conference publication: VIRCHOWS ARCHIV. 2011;459:S133-S134
- Book chapter: CANCER CYTOGENETICS. 2010;p. 415-428
- Review: CANCER LETTERS. 2008;265(1):1-15
- Meeting abstract: LUNG CANCER. 2006;54:S15
- Conference publication: CANCER RESEARCH. 2006;66(8)
- Conference publication: TOXICOLOGY AND APPLIED PHARMACOLOGY. 2004;197(3):261
- Show more